Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Vaxcyte, Inc. (NASDAQ:PCVX). In a filing disclosed on May 06th, the Representative disclosed that they had bought between $1,001 and $15,000 in Vaxcyte stock on April 14th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of Beiersdorf Aktiengesellschaft OTCMKTS: BDRFF on 5/2/2025.
• Purchased $1,001 - $15,000 in shares of Alkami Technology NASDAQ: ALKT on 4/30/2025.
• Purchased $1,001 - $15,000 in shares of Merck & Co., Inc. NYSE: MRK on 4/29/2025.
• Sold $1,001 - $15,000 in shares of DXC Technology NYSE: DXC on 4/29/2025.
• Sold $1,001 - $15,000 in shares of DOW NYSE: DOW on 4/29/2025.
• Sold $1,001 - $15,000 in shares of Zions Bancorporation, National Association NASDAQ: ZION on 4/29/2025.
• Purchased $1,001 - $15,000 in shares of O'Reilly Automotive NASDAQ: ORLY on 4/29/2025.
• Purchased $1,001 - $15,000 in shares of McKesson NYSE: MCK on 4/29/2025.
• Sold $1,001 - $15,000 in shares of Amazon.com NASDAQ: AMZN on 4/29/2025.
• Sold $1,001 - $15,000 in shares of Humana NYSE: HUM on 4/29/2025.

Vaxcyte Stock Down 0.9 %

PCVX stock traded down $0.29 during mid-day trading on Friday, hitting $31.16. 2,030,375 shares of the company were exchanged, compared to its average volume of 1,306,324. Vaxcyte, Inc. has a 12-month low of $27.66 and a 12-month high of $121.06. The firm has a market capitalization of $4.02 billion, a P/E ratio of -6.77 and a beta of 1.27. The business has a fifty day simple moving average of $47.44 and a 200-day simple moving average of $75.28.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.02). During the same quarter in the previous year, the business posted ($0.85) EPS. Research analysts predict that Vaxcyte, Inc. will post -4.21 EPS for the current year.

Hedge Funds Weigh In On Vaxcyte

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC acquired a new position in shares of Vaxcyte in the 3rd quarter valued at $355,000. Everence Capital Management Inc. purchased a new position in shares of Vaxcyte during the fourth quarter worth about $301,000. Diversified Trust Co acquired a new stake in shares of Vaxcyte during the fourth quarter worth about $1,433,000. Harbor Capital Advisors Inc. lifted its holdings in shares of Vaxcyte by 15.8% in the 4th quarter. Harbor Capital Advisors Inc. now owns 74,907 shares of the company's stock valued at $6,132,000 after purchasing an additional 10,243 shares during the last quarter. Finally, Nisa Investment Advisors LLC boosted its position in shares of Vaxcyte by 21.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,684 shares of the company's stock valued at $220,000 after purchasing an additional 475 shares during the period. 96.78% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, COO Jim Wassil sold 8,000 shares of the business's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $73.27, for a total value of $586,160.00. Following the transaction, the chief operating officer now owns 154,931 shares in the company, valued at $11,351,794.37. The trade was a 4.91 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. 3.10% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on PCVX. Bank of America dropped their target price on Vaxcyte from $157.00 to $137.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. Guggenheim reaffirmed a "buy" rating and set a $160.00 target price on shares of Vaxcyte in a research note on Wednesday, March 12th. The Goldman Sachs Group reduced their target price on shares of Vaxcyte from $138.00 to $100.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st. Evercore ISI upgraded shares of Vaxcyte to a "strong-buy" rating in a research note on Monday, March 31st. Finally, Cantor Fitzgerald started coverage on Vaxcyte in a research note on Tuesday, April 22nd. They issued an "overweight" rating for the company. Nine equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $136.50.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.